Compare GFF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | IDYA |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | GFF | IDYA |
|---|---|---|
| Price | $74.29 | $33.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $95.75 | $49.42 |
| AVG Volume (30 Days) | 360.9K | ★ 850.2K |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $2,519,926,000.00 | $214,834,000.00 |
| Revenue This Year | $1.87 | $2,434.86 |
| Revenue Next Year | $3.39 | N/A |
| P/E Ratio | $68.01 | ★ N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $63.92 | $13.45 |
| 52 Week High | $84.42 | $36.55 |
| Indicator | GFF | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 58.37 |
| Support Level | $65.01 | $32.50 |
| Resistance Level | $76.07 | $36.55 |
| Average True Range (ATR) | 2.76 | 1.47 |
| MACD | 0.69 | -0.01 |
| Stochastic Oscillator | 83.91 | 50.19 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.